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AbstrAct
Objective
To assess the risks and benefits of P2Y12 inhibitor 
monotherapy compared with dual antiplatelet therapy 
(DAPT) and whether these associations are modified 
by patients’ characteristics.
Design
Individual patient level meta-analysis of randomised 
controlled trials.
Data sOurces
Searches were conducted in Ovid Medline, Embase, 
and three websites (www.tctmd.com, www.escardio.
org, www.acc.org/cardiosourceplus) from inception to 
16 July 2020. The primary authors provided individual 
participant data.
eligibility criteria
Randomised controlled trials comparing effects of oral 
P2Y12 monotherapy and DAPT on centrally adjudicated 
endpoints after coronary revascularisation in patients 
without an indication for oral anticoagulation.
Main OutcOMe Measures
The primary outcome was a composite of all cause 
death, myocardial infarction, and stroke, tested for 
non-inferiority against a margin of 1.15 for the hazard 
ratio. The key safety endpoint was Bleeding Academic 
Research Consortium (BARC) type 3 or type 5 bleeding.
results
The meta-analysis included data from six trials, 
including 24 096 patients. The primary outcome 
occurred in 283 (2.95%) patients with P2Y12 inhibitor 
monotherapy and 315 (3.27%) with DAPT in the 
per protocol population (hazard ratio 0.93, 95% 
confidence interval 0.79 to 1.09; P=0.005 for non-
inferiority; P=0.38 for superiority; τ2=0.00) and 
in 303 (2.94%) with P2Y12 inhibitor monotherapy 
and 338 (3.36%) with DAPT in the intention to treat 
population (0.90, 0.77 to 1.05; P=0.18 for superiority; 
τ2=0.00). The treatment effect was consistent across 
all subgroups, except for sex (P for interaction=0.02), 
suggesting that P2Y12 inhibitor monotherapy lowers 
the risk of the primary ischaemic endpoint in women 
(hazard ratio 0.64, 0.46 to 0.89) but not in men 
(1.00, 0.83 to 1.19). The risk of bleeding was lower 
with P2Y12 inhibitor monotherapy than with DAPT (97 
(0.89%) v 197 (1.83%); hazard ratio 0.49, 0.39 to 
0.63; P<0.001; τ2=0.03), which was consistent across 
subgroups, except for type of P2Y12 inhibitor (P for 
interaction=0.02), suggesting greater benefit when a 
newer P2Y12 inhibitor rather than clopidogrel was part 
of the DAPT regimen.
cOnclusiOns
P2Y12 inhibitor monotherapy was associated with a 
similar risk of death, myocardial infarction, or stroke, 
with evidence that this association may be modified 




Inhibition of platelet P2Y12 receptor signalling plays 
a central role in the secondary prevention of cardiac 
or cerebrovascular thrombotic complications.1-3 Oral 
P2Y12 inhibitors have mainly been investigated in 
combination with aspirin after coronary revasculari-
sation.2-4 In this context, robust evidence shows 
that dual antiplatelet therapy (DAPT), consisting 
of aspirin and an oral P2Y12 inhibitor, mitigates the 
incidence of ischaemic events but increases the risk 
of major bleeding compared with aspirin alone.1  2 A 
few studies have assessed oral P2Y12 inhibitor mono-
therapy as an alternative to conventional DAPT.5-10 
However, none was powered to assess whether 
withdrawal of aspirin and continuation with an 
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WhAt Is AlreAdy knoWn on thIs topIc
Aggregate data meta-analyses comparing P2Y12 inhibitor monotherapy with dual 
antiplatelet therapy (DAPT) in patients undergoing coronary revascularisation 
have been conducted
They generally showed similar risks of ischaemic events and lower risks of 
bleeding with P2Y12 inhibitor monotherapy than with DAPT
Previous meta-analyses did not account for the initial DAPT phase, usually 
common to both experimental and control groups, and almost invariably failed to 
provide information on subgroups of interest
WhAt thIs study Adds
P2Y12 inhibitor monotherapy was associated with a similar risk of fatal and 
ischaemic events and lower rates of major bleeding compared with DAPT
P2Y12 inhibitor monotherapy may be particularly beneficial among female 
patients, owing to an association with lower cardiovascular mortality
Aspirin cessation from one to three months after coronary revascularisation and 
continuation with P2Y12 inhibitor monotherapy may be warranted instead of 
continuation of DAPT, especially in women
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oral P2Y12 inhibitor preserves the treatment effect 
of the latter in combination with aspirin.11 Previous 
aggregate data meta-analyses of oral P2Y12 inhibitor 
monotherapy studies included events occurring during 
the initial DAPT phase, which was identical in both 
experimental and control regimens in most studies, 
and have therefore not conclusively ascertained the 
risks and benefits of aspirin withdrawal; nor did they 
explore the consistency of treatment effects across 
subgroups.12-14 Therefore, concerns remain that 
removal of aspirin after a short course of DAPT may, 
from that moment onwards, be associated with a higher 
risk of ischaemic events, especially among patients 
with high risk features.3 As a reflection of the residual 
uncertainties about the trade-off between risks and 
benefits of aspirin withdrawal in this setting, the 2020 
European Society of Cardiology guidelines for the 
management of acute coronary syndromes in patients 
presenting without ST segment elevation state that 
discontinuation of aspirin after a three to six month 
course of DAPT, and continuation with P2Y12 inhibitor 
monotherapy, should be considered depending on the 
balance between ischaemic risk and bleeding risk.15 
The American Heart Association/American College 
of Cardiology guidelines have not yet issued a formal 
recommendation for this treatment option.1
We did a systematic review and individual partici-
pant data meta-analysis of all randomised trials that 
compared P2Y12 inhibitor monotherapy with DAPT 
among patients who underwent coronary revascula-
risation, with a focus on the preservation of the 
treatment effect after aspirin removal, and investigated 
its consistency across predefined subgroups.
Methods
We conducted a systematic review and individual 
participant data meta-analysis to answer the following 
PICOS question: in patients who have undergone 
percutaneous or surgical revascularisation for stable 
or unstable coronary artery disease, is P2Y12 inhibitor 
monotherapy at least similarly effective for a composite 
of fatal and cardiovascular ischaemic endpoints and, 
if so, safer for bleeding endpoints, compared with 
DAPT among randomised trials that reported centrally 
adjudicated outcome data?
We excluded trials including patients with a 
concomitant indication for oral anticoagulation under 
the rationale that concomitant oral anticoagulation 
further increases the risk of bleeding and mitigates the 
risk of ischaemic recurrences after aspirin withdrawal, 
and long term DAPT is no longer considered a valid 
standard of care in this setting.16 We implemented 
no further restrictions for study selection, such as 
the number of participants or duration of follow-up. 
Methods and reporting follow the guidelines of the 
Preferred Reporting Items for a Systematic Review and 
Meta-analysis of Individual Participant Data (PRISMA-
IPD).17 The study protocol was prospectively registered 
on PROSPERO (international prospective register of 
systematic reviews) and is available online (www.crd.
york.ac.uk/prospero, CRD42020176853).
search strategy
Two investigators (MV, FG) determined trial eligibility 
criteria; a third investigator (RM) was involved in case 
of disagreement. Randomised trials were identified 
by a search in Ovid Medline, Embase, and three 
websites (www.tctmd.com, www.escardio.org, www.
acc.org/cardiosourceplus). Reference lists of retrieved 
articles were hand searched. We imposed no language 
restrictions. The search strategy is provided in the 
appendix.
Outcome measures
The pre-specified primary efficacy endpoint was the 
composite of all cause death, myocardial infarction, 
and stroke throughout the duration of the randomised 
comparison of protocol mandated P2Y12 inhibitor 
monotherapy versus DAPT. The key safety endpoint 
was Bleeding Academic Research Consortium (BARC) 
type 3 or type 5 bleeding.18 Other secondary endpoints 
are shown in the appendix. The outcome definitions 
were largely consistent among the included trials 
(supplementary methods).
Data extraction and quality assessment
We contacted the principal investigators of the 
eligible trials, requesting individual participant data 
to be provided in an anonymised electronic dataset 
(supplementary methods). We checked data for 
completeness and consistency and compared them 
with the results of the original publications. We 
contacted the principal investigators of the included 
trials in case of missing data or when queries emerged 
during the integrity checks. Once queries had been 
resolved, the clean data were uploaded to the main 
study dataset. For one trial,10 587 (8.2%) patients 
were excluded from this analysis owing to the lack of 
approval to share the data from the country’s legal 
and regulatory authorities. Two investigators (MV, 
FG) independently assessed the quality of included 
trials by using the Cochrane Collaboration’s tool for 
assessing the risk of bias 2 (supplementary table 
D).19 Disagreements were resolved first by discussion 
and then by consulting a third investigator (RM) 
for arbitration. Each trial had been approved by its 
local medical ethics committee, and all patients had 
provided written informed consent.
Data synthesis
We pre-specified a one step approach to model the data 
from all trials simultaneously using a mixed effect Cox 
regression model with baseline hazards stratified by 
trial and a random intercept to account for variation 
between trials in treatment effect. Treatment effects 
were derived as hazard ratios and 95% confidence 
intervals. We quantified the heterogeneity of the 
treatment effect between trials by using the variance 
of the random slope τ2. Pre-specified sensitivity 
analyses were based on a two step approach using a 
DerSimonian-Laird random effects model to combine 
trial level estimates. We used I2 to estimate between 
trial heterogeneity for the two step model.
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All primary analyses were conducted with censoring 
of events that occurred during the initial DAPT phase, if 
present, common to both experimental and treatment 
groups, and included only events occurring after the 
time when the protocol specified the change from DAPT 
to P2Y12 inhibitor monotherapy in the experimental 
group. Data were analysed up to the longest available 
time point with protocol specified P2Y12 inhibitor 
monotherapy in the experimental group and DAPT in 
the control group.
We first tested the non-inferiority of P2Y12 inhibitor 
monotherapy compared with DAPT on the primary 
efficacy endpoint at a one sided α of 0.05 and a non-
inferiority margin of 1.15 on the hazard ratio scale. 
Under the rationale that aspirin was omitted in the 
experimental arm of P2Y12 inhibitor monotherapy, 
while being continued in the DAPT group, we chose this 
non-inferiority margin because it represents 50% of 
the treatment effect of aspirin compared with placebo 
or standard care observed by the Antithrombotic 
Trialists’ Collaboration in patients with previous 
myocardial infarction for the composite endpoint of 
vascular death, myocardial infarction, and stroke.11 
If non-inferiority was met, we pre-specified testing 
of the superiority of P2Y12 inhibitor monotherapy at 
a two sided α of 0.05. We did superiority analyses 
in the intention to treat population and the non-
inferiority analysis in the per protocol population. 
We reported the one sided P value for non-inferiority 
only for the primary per protocol analysis; for all 
remaining analyses, we reported two sided P values 
for superiority and two sided 95% confidence intervals 
to allow conventional interpretation of the results. 
The per protocol population was pre-specified and 
excluded ineligible patients (that is, those violating 
inclusion/exclusion criteria) and/or those who never 
received allocated treatment strategy. We pre-specified 
a set of subgroup analyses for the primary efficacy 
endpoint and the key safety endpoint according to age, 
sex, clinical presentation, diabetes mellitus, history 
of chronic kidney disease, peripheral artery disease, 
bleeding risk, complexity of percutaneous coronary 
intervention, left main or left anterior descending 
percutaneous intervention, type of revascularisation 
(percutaneous or surgical), type of P2Y12 inhibitor 
in the comparator and experimental therapies, use 
of proton pump inhibitor, and geographical region, 
accompanied by tests of interaction. Further details on 
data analysis are reported in the appendix.
Patient and public involvement
Patients and public were not directly involved in this 
individual participant data meta-analysis. However, 
we acknowledge their contribution in performing 




We screened 13 240 unique citations. Of these, 820 
were judged potentially eligible during screening of 
titles and abstracts, and six were deemed eligible after 
full text review (supplementary figure A). We sought 
and obtained individual participant data for all eligi-
ble trials. The appendix describes trial characteristics 
and patient populations (supplementary tables A and 
B). The definitions used for outcomes were largely 
consistent across trials (supplementary table C), and 
the risk of bias assessment identified some concerns 
for five of six trials related to the open label alloca-
tion of the treatment assignment (supplementary 
table D). All six studies were sponsored by academic 
organisations.
We considered 24 096 participants for the primary 
analysis, of whom 12 037 (50%) were randomly 
allocated to P2Y12 inhibitor monotherapy and 12 059 
(50%) to DAPT. We excluded 788 (3.3%) patients 
owing to premature study termination or death before 
the time point at which each study protocol specified 
the implementation of P2Y12 inhibitor monotherapy in 
the experimental group (four trials) or owing to lack 
of approval to share the data from the Chinese legal 
and regulatory authorities for 8.2% of the patients 
recruited in one trial. Therefore, 23 308 patients were 
available for the intention to treat analysis, including 
11 634 (49.9%) patients assigned to P2Y12 inhibitor 
monotherapy (clopidogrel in 2586 (22.2%), prasugrel 
in 92 (0.8%), ticagrelor in 8956 (77.0%)) and 11 674 
(50.1%) to DAPT (aspirin and clopidogrel 4297 
(36.8%), aspirin and prasugrel 140 (1.2%), aspirin 
and ticagrelor 7237 (62.0%)). A total of 1347 (5.8%) 
participants were excluded from the per protocol 
population (supplementary figure B). The median 
treatment duration was 334 days (range 9-12 months).
Patient characteristics
Baseline clinical characteristics were balanced 
between groups (table 1 and supplementary table E). 
The mean age was 65 years, and 5423 (23.3%) patients 
were female. A total of 7419 (31.8%) patients had a 
history of diabetes, and 3823 (16.6%) had chronic 
kidney failure. History of myocardial infarction, 
percutaneous coronary intervention, or coronary 
artery bypass surgery was noted in 4438 (19.0%), 
6959 (30.3%), and 1250 (5.4%) patients, respectively. 
At presentation, most patients (13 966; 59.9%) had an 
acute coronary syndrome. Procedural characteristics 
are shown in supplementary tables E and F.
efficacy endpoints
The composite endpoint of all cause death, myocardial 
infarction, and stroke occurred in 283 (2.95%) patients 
with P2Y12 inhibitor monotherapy and 315 (3.27%) 
patients with DAPT in the per protocol population, 
fulfilling non-inferiority (P=0.005 for non-inferiority 
with one sided α of 5%), but not superiority (hazard 
ratio 0.93, 95% confidence interval 0.79 to 1.09; 
P=0.38), with no between trial heterogeneity (τ2=0.00) 
(table 2). The same composite endpoint occurred in 
303 (2.94%) and 338 (3.36%) patients with P2Y12 
inhibitor monotherapy and DAPT, respectively, in the 
intention to treat population (hazard ratio 0.90, 0.77 
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to 1.05; P=0.18), with no between trial heterogeneity 
(τ2=0.00) (table 2; fig 1).
P2Y12 inhibitor monotherapy was not associated 
with a lower risk of all cause death (0.98% with 
monotherapy versus 1.40% with DAPT; hazard ratio 
0.80, 0.62 to 1.03), but the risk of cardiovascular 
death was lower with P2Y12 inhibitor monotherapy 
(0.57% v 0.90%; 0.69, 0.50 to 0.95), with no between 
trial heterogeneity (τ2=0.00). The risks of myocardial 
infarction (1.64% with monotherapy versus 1.79% 
with DAPT; hazard ratio 0.93, 0.75 to 1.14), stroke 
(0.51% v 0.41%; 1.10, 0.73 to 1.64), definite stent 
thrombosis (0.24% v 0.28%; 0.85, 0.48 to 1.50), and 
definite or probable stent thrombosis (0.27% v 0.34%; 
0.81, 0.49 to 1.37) did not differ (table 2).
The treatment effect for the primary ischaemic 
endpoint was consistent across most of the pre-
defined subgroups, in both intention to treat and per 
protocol analyses (fig 2). We observed a treatment-by-
subgroup interaction with sex (P for interaction=0.02), 
suggesting that P2Y12 inhibitor monotherapy lowers 
the risk of the primary ischaemic endpoint in women 
(hazard ratio 0.64, 0.46 to 0.89) but not in men (1.00, 
0.83 to 1.19) (fig 2). This corresponded to a number 
needed to treat to benefit of 72 (95% confidence 
interval 42 to 250) in women but no benefit in 
men. These findings remained consistent in the per 
protocol analysis (supplementary figure C). When the 
components of the primary efficacy endpoint were 
stratified by sex, a treatment-by-sex interaction existed 
table 1 | baseline characteristics. values are numbers (percentages) unless stated otherwise
characteristics
Primary study population 
(n=23 308)
P2y12 inhibitor  
(n=11 634)
aspirin + P2y12 inhibitor 
(n=11 674)
Difference  
(95% ci) P value
Study ID:          
 DACAB 334 (1.4) 166 (1.4) 168 (1.4) 0.0% (–0.3% to 0.3%) 0.95
 GLASSY 7509 (32.2) 3753 (32.3) 3756 (32.2) 0.1% (–1.1% to 1.3%) 0.90
 SMART-CHOICE 2926 (12.6) 1455 (12.5) 1471 (12.6) –0.1% (–0.9% to 0.8%) 0.84
 STOPDAPT-2 3003 (12.9) 1496 (12.9) 1507 (12.9) –0.1% (–0.9% to 0.8%) 0.92
 TICO 3004 (12.9) 1499 (12.9) 1505 (12.9) –0.0% (–0.9% to 0.9%) >0.99
 TWILIGHT 6532 (28.0) 3265 (28.1) 3267 (28.0) 0.1% (–1.1% to 1.2%) 0.89
Mean (SD) age, years 64.8 (10.6) (n=23 308) 64.8 (10.6) (n=11 634) 64.9 (10.6) (n=11 674) –0.1 (–0.3 to 0.2) 0.58
Age ≥65 years 12 194 (52.3) 6094 (52.4) 6100 (52.3) 0.1% (–1.2% to 1.4%) 0.85
Female sex 5423 (23.3) 2717 (23.4) 2706 (23.2) 0.2% (–0.9% to 1.3%) 0.75
Mean (SD) height, m 1.7 (0.1) (n=22 951) 1.7 (0.1) (n=11 455) 1.7 (0.1) (n=11 496) 0.0 (–0.0 to 0.0) 0.32
Mean (SD) weight, kg 76.6 (17.3) (n=22 958) 76.7 (17.3) (n=11 461) 76.5 (17.2) (n=11 497) 0.2 (–0.3 to 0.6) 0.42
Mean (SD) body mass index 26.9 (4.8) (n=22 948) 26.9 (4.8) (n=11 455) 26.9 (4.8) (n=11 493) 0.0 (–0.1 to 0.1) 0.79
Geographical region:   0.99
 Asia 10 318 (44.3) 5146 (44.2) 5172 (44.3) –0.1% (–1.3% to 1.2%) 0.91
 North America 2972 (12.8) 1484 (12.8) 1488 (12.7) 0.0% (–0.8% to 0.9%) 0.98
 Western Europe 7848 (33.7) 3917 (33.7) 3931 (33.7) –0.0% (–1.2% to 1.2%) >0.99
 Eastern Europe 2170 (9.3) 1087 (9.3) 1083 (9.3) 0.1% (–0.7% to 0.8%) 0.87
Diabetes mellitus 7419/23 304 (31.8) 3744/11 630 (32.2) 3675/11 674 (31.5) 0.7% (–0.5% to 1.9%) 0.24
Insulin treated diabetes 1543/21 104 (7.3) 746/10 547 (7.1) 797/10 557 (7.5) –0.5% (–1.2% to 0.2%) 0.18
Current cigarette smoker 6271/23 299 (26.9) 3134/11 630 (26.9) 3137/11 669 (26.9) 0.1% (–1.1% to 1.2%) 0.91
Hypercholesterolaemia 14 695/23 030 (63.8) 7298/11 494 (63.5) 7397/11 536 (64.1) –0.6% (–1.9% to 0.6%) 0.32
Hypertension 16 005/23 286 (68.7) 7985/11 624 (68.7) 8020/11 662 (68.8) –0.1% (–1.3% to 1.1%) 0.90
Liver disease 33/20 048 (0.2) 21/10 013 (0.2) 12/10 035 (0.1) 0.1% (–0.0% to 0.2%) 0.11
Peripheral artery disease 1323/20 267 (6.5) 633/10 114 (6.3) 690/10 153 (6.8) –0.5% (–1.2% to 0.1%) 0.12
Previous myocardial infarction 4438/23 297 (19.0) 221/11 626 (19.1) 2217/11 671 (19.0) 0.1% (–0.9% to 1.1%) 0.83
Previous PCI 6959/22 966 (30.3) 3440/11 464 (30.0) 3519/11 502 (30.6) –0.6% (–1.8% to 0.6%) 0.33
Previous CABG 1250/23 300 (5.4) 606/11 629 (5.2) 644/11 671 (5.5) –0.3% (–0.9% to 0.3%) 0.29
Previous stroke 733/23 298 (3.1) 343/11 626 (3.0) 390/11 672 (3.3) –0.4% (–0.8% to 0.1%) 0.09
Previous bleeding 265/23 291 (1.1) 132/11 623 (1.1) 133/11 668 (1.1) 0.0% (–0.3% to 0.3%) 0.97
History of chronic kidney disease 3823/23 031 (16.6) 1892/11 491 (16.5) 1931/11 540 (16.7) –0.3% (–1.2% to 0.7%) 0.58
Chronic lung disease 826/17 238 (4.8) 403/8609 (4.7) 423/8629 (4.9) –0.2% (–0.9% to 0.4%) 0.49
Clinical presentation: (n=23 305) (n=11 633) (n=11 672)   0.53
 Chronic coronary syndrome 9339 (40.1) 4685 (40.3) 4654 (39.9) 0.4% (–0.9% to 1.7%) 0.53
 Acute coronary syndrome 13 966 (59.9) 6948 (59.7) 7018 (60.1) –0.4% (–1.7% to 0.9%) 0.53
  Unstable angina 5579 (39.9) 2752 (39.6) 2827 (40.3) –0.7% (–2.3% to 1.0%) 0.41
  Non-STEMI 5122 (36.7) 2543 (36.6) 2579 (36.7) –0.1% (–1.7% to 1.5%) 0.86
  STEMI 3265 (23.4) 1653 (23.8) 1612 (23.0) 0.8% (–0.6% to 2.2%) 0.25
Aspirin on admission 13 182/20 301 (64.9) 6581/10 137 (64.9) 6601/10 164 (64.9) 0.0% (–1.3% to 1.3%) 0.97
Mean (SD) PRECISE-DAPT score* 16.7 (9.7) (n=22 018) 16.7 (9.6) (n=10 972) 16.8 (9.7) (n=11 046) –0.1 (–0.3 to 0.2) 0.55
PRECISE-DAPT score ≥25 3928/22 018 (17.8) 1941/10 972 (17.7) 1987/11 046 (18.0) –0.3% (–1.3% to 0.7%) 0.56
Median (IQR) creatinine clearance 
(MDRD), mL/min 84.4 (70.0-100.0) (n=22 961)
84.7 (70.1-100.2) 
(n=11 455) 84.2 (69.7-99.8) (n=11 506) 0.2 (–2.2 to 2.6) 0.19
Mean (SD) haemoglobin, g/dL 19.8 (27.3) (n=22 639) 19.8 (26.9) (n=11 295) 19.9 (27.6) (n=11 344) –0.1 (–0.8 to 0.6) 0.74
Mean (SD) LVEF, % 56.4 (11.1) (n=13 742) 56.3 (11.0) (n=6851) 56.4 (11.2) (n=6891) –0.1 (–0.5 to 0.3) 0.64
ACS=acute coronary syndrome; CABG=coronary artery bypass grafting; CCS=chronic coronary syndrome; LVEF=left ventricular ejection fraction; MDRD=Modification of Diet in Renal Disease; 
PCI=percutaneous coronary intervention; STEMI=ST-segment elevation myocardial infarction.
*Includes five items: age, creatinine clearance, white blood cell count, haemoglobin, and history of bleeding.
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for all cause death (P for interaction=0.02) attributable 
to cardiovascular death (P for interaction=0.02), 
which was markedly reduced among women (hazard 
ratio 0.31, 0.15 to 0.65) but not men (0.86, 0.59 to 
1.25) with P2Y12 inhibitor monotherapy (fig 3). The 
treatment effects for the primary efficacy endpoint 
or its components were consistent with respect to 
clopidogrel or newer P2Y12 inhibitors, consisting of 
mainly ticagrelor, in the experimental arm (fig 4). In 
an analysis restricted to trials with monotherapy with 
newer P2Y12 inhibitors, the effect of monotherapy 
was consistent across subgroups except for sex (P for 
interaction=0.02) (supplementary figure D). In an 
analysis restricted to trials with monotherapy with 
clopidogrel, the effect of monotherapy was consistent 
across all subgroups (supplementary figure E).
safety endpoints
We found strong evidence for a reduction in the risk 
of BARC type 3 or type 5 bleeding among patients 
randomly allocated to P2Y12 inhibitor monotherapy 
compared with DAPT (0.89% v 1.83%; hazard ratio 
0.49, 0.39 to 0.63; P<0.001; τ2=0.03), for a number 
needed to treat to benefit of 111 (77 to 200) over a 
median treatment duration of 334 days (table 2; fig 5). 
The treatment effect was consistent across pre-defined 
subgroups (supplementary figure F), with the exception 
of a treatment-by-subgroup interaction for type of 
P2Y12 inhibitor in the control group (hazard ratio 0.77 
(0.50 to 1.18) for clopidogrel and 0.41 (0.30 to 0.55) 
for newer P2Y12 inhibitors; P for interaction=0.02) 
(supplementary figure F). The use of a newer P2Y12 
inhibitor was associated with treatment-by-subgroup 
interactions for clinical presentation (acute versus 
chronic coronary syndrome) and type of P2Y12 
inhibitor in the control group (supplementary figure 
G). Clopidogrel monotherapy provided consistent 
treatment effects across pre-defined subgroups 
(supplementary figure H). The rates of other bleeding 
endpoints or net adverse clinical events were reduced 
with P2Y12 inhibitor monotherapy (table 2).
Pre-specified sensitivity analyses
Sensitivity analyses including the initial DAPT 
phase after randomisation, which was identical in 
both treatment groups in four trials, yielded no 
difference for the composite ischaemic endpoint, with 
attenuated absolute and relative bleeding benefits 
with P2Y12 inhibitor monotherapy (supplementary 
table H). Additional sensitivity analyses excluding 
patients who experienced non-fatal ischaemic events 
(supplementary tables I and J), bleeding events 
(supplementary tables K and L), or any of these events 
(supplementary table M) during the initial DAPT 
phase provided consistent findings. All cause death 
occurred in 144 (0.98%) patients with P2Y12 inhibitor 
table 2 | clinical outcomes in intention to treat and per protocol populations. values are number of events/number of patients at risk (% cumulative 
incidence) unless stated otherwise
Outcome






Hazard ratio  






Hazard ratio  
(95% ci) τ2 P value
Death, MI, or stroke* 303 (2.94) 338 (3.36) 0.90 (0.77 to 1.05) 0.00 0.18 283 (2.95) 315 (3.27) 0.93 (0.79 to 1.09) 0.00 0.38
Death or MI 259 (2.49) 299 (3.0) 0.87 (0.74 to 1.03) 0.00 0.10 245 (2.53) 287 (2.99) 0.88 (0.74 to 1.05) 0.00 0.15
Death:                    
 All cause 107 (0.98) 137 (1.40) 0.80 (0.62 to 1.03) 0.00 0.08 107 (1.05) 128 (1.36) 0.88 (0.68 to 1.15) 0.01 0.35
 Cardiovascular 61 (0.57) 90 (0.90) 0.69 (0.50 to 0.95) 0.00 0.03 61 (0.61) 83 (0.86) 0.77 (0.56 to 1.08) 0.00 0.13
 Non-cardiovascular 42 (0.38) 42 (0.46) 1.03 (0.67 to 1.58) 0.15 0.89 42 (0.40) 41 (0.46) 1.10 (0.71 to 1.70) 0.19 0.66
 MI 167 (1.64) 181 (1.79) 0.93 (0.75 to 1.14) 0.01 0.47 153 (1.61) 177 (1.81) 0.89 (0.72 to 1.10) 0.01 0.28
Stroke:                    
 Any 51 (0.51) 45 (0.41) 1.10 (0.73 to 1.64) 0.09 0.65 45 (0.48) 34 (0.32) 1.32 (0.84 to 2.08) 0.00 0.22
 Ischaemic 38 (0.39) 36 (0.33) 1.01 (0.63 to 1.60) 0.07 0.98 35 (0.39) 27 (0.26) 1.27 (0.76 to 2.11) 0.00 0.35
 Haemorrhagic 6 (0.05) 2 (0.02) 2.53 (0.49 to 13.0) 0.00 0.26 5 (0.05) 2 (0.02) 2.21 (0.40 to 12.09) 0.00 0.36
Stent thrombosis:                    
 Definite 23 (0.24) 26 (0.28) 0.85 (0.48 to 1.50) 0.00 0.56 17 (0.20) 25 (0.28) 0.72 (0.38 to 1.33) 0.00 0.29
 Probable 6 (0.05) 7 (0.06) 0.72 (0.23 to 2.26) 0.00 0.57 4 (0.04) 7 (0.06) 0.51 (0.13 to 2.06) 0.00 0.34
 Possible 27 (0.26) 48 (0.52) 0.56 (0.35 to 0.90) 0.00 0.02 27 (0.28) 47 (0.53) 0.59 (0.37 to 0.94) 0.00 0.03
 Definite or probable 27 (0.27) 32 (0.34) 0.81 (0.49 to 1.37) 0.00 0.43 21 (0.23) 31 (0.34) 0.68 (0.38 to 1.19) 0.00 0.17
 Any 52 (0.52) 79 (0.85) 0.65 (0.46 to 0.92) 0.00 0.02 47 (0.51) 77 (0.86) 0.61 (0.42 to 0.88) 0.00 0.008
BARC bleeding:                    
 2, 3, or 5 295 (2.91) 493 (4.76) 0.59 (0.51 to 0.69) 0.00 <0.001 277 (2.93) 475 (4.76) 0.60 (0.52 to 0.70) 0.00 <0.001
 3 or 5 97 (0.89) 197 (1.83) 0.49 (0.39 to 0.63) 0.03 <0.001 91 (0.90) 176 (1.71) 0.53 (0.41 to 0.69) 0.03 <0.001
 5 3 (0.03) 5 (0.06) 0.67 (0.11 to 4.02) 0.00 0.66 3 (0.04) 5 (0.06) 0.69 (0.11 to 4.12) 0.00 0.68
TIMI bleeding:                    
 Major 44 (0.45) 93 (0.94) 0.47 (0.33 to 0.68) 0.29 <0.001 44 (0.48) 82 (0.87) 0.55 (0.38 to 0.79) 0.20 0.001
 Minor 136 (1.43) 242 (2.4) 0.56 (0.45 to 0.69) 0.00 <0.001 132 (1.48) 230 (2.37) 0.57 (0.46 to 0.71) 0.00 <0.001
 Major or minor 179 (1.88) 331 (3.33) 0.53 (0.45 to 0.64) 0.04 <0.001 175 (1.96) 309 (3.25) 0.56 (0.47 to 0.68) 0.04 <0.001
NACE 384 (3.69) 504 (4.94) 0.76 (0.67 to 0.87) 0.02 <0.001 359 (3.71) 460 (4.71) 0.81 (0.70 to 0.93) 0.01 0.002
BARC=Bleeding Academy Research Consortium; MI=myocardial infarction; NACE=net adverse clinical events, defined as composite of all cause death, myocardial infarction, stroke, and BARC type 
3 or type 5 bleeding; TIMI=Thrombolysis in Myocardial Infarction.
*P value for non-inferiority=0.005 in per protocol population; non-inferiority testing was performed on one sided α of 5% corresponding to 90% CIs; other P values are two sided for superiority; 
95% CIs are shown.
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monotherapy and 173 (1.31%) with DAPT (hazard 
ratio 0.85, 0.68 to 1.06; P=0.14; τ2=0.00) when 
GLOBAL LEADERS instead of GLASSY was pooled with 
the other trials. An on-treatment analysis, excluding 
one trial due to lack of information,9 showed no excess 
of ischaemic events and lower bleeding risk with P2Y12 
inhibitor monotherapy (supplementary table N).
additional post hoc analyses
The composite endpoint of all-cause death, myocar-
dial infarction, and stroke, censoring events that 
occurred nine months after the start of P2Y12 inhibitor 
monotherapy in the experimental arm (to achieve a 
uniform length of follow-up across trials), occurred 
in 259 (2.28%) and 240 (2.28%) patients with P2Y12 
inhibitor monotherapy and in 284 (2.49%) and 262 
(2.39%) with DAPT in the intention to treat (hazard 
ratio 0.92, 0.77 to 1.08; P=0.31 for superiority) and per 
protocol (0.95, 0.80 to 1.13; P=0.58 for superiority) 
populations, respectively, with no between trial 
heterogeneity (τ2=0.00) (supplementary table O). We 
observed no treatment-by-subgroup interaction with 
body weight for the primary efficacy endpoint when 
both sexes were appraised separately, suggesting 
consistent benefit with P2Y12 inhibitor monotherapy 
among women but not men, irrespective of body 
weight (supplementary figure I). The treatment-by-sex 
interaction testing for the primary outcome in each 
included study is shown in supplementary figure J.
discussion
Our individual participant data meta-analysis of the 
totality of available randomised studies investigating 
P2Y12 inhibitor monotherapy after revascularisation, 
including 24 096 patients mainly after percutaneous 
coronary intervention, provides strong evidence that 
P2Y12 inhibitor monotherapy is non-inferior to DAPT. 
We chose a non-inferiority margin that preserved 
half of the treatment effect of aspirin observed in the 
historical aspirin trials,11 under the rationale that 
the experimental arm consists of aspirin withdrawal 
and that the treatment effect of DAPT versus placebo 
is not known. P2Y12 inhibitor monotherapy was 
associated with a lower risk of major bleeding and net 
adverse clinical events compared with DAPT. The main 
findings were corroborated by all sensitivity analyses. 
Our analysis suggests that female patients may derive 
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Fig 1 | Hazard ratios for individual trials and for pooled population and Kaplan-Meier estimates for primary endpoint of all cause death, myocardial 
infarction, or stroke in intention to treat population. Kaplan-Meier curves and hazard ratios from one step, fixed effect meta-analysis (top) and two 
step, fixed effect meta-analysis (bottom). DaPt=dual antiplatelet therapy; P2y12i=P2y12 inhibitor monotherapy
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owing to the lower risk of major adverse cardiovascular 
events, largely driven by a reduction in cardiovascular 
death. P2Y12 inhibitor monotherapy was associa-
ted with lower bleeding rates consistently across 
subgroups, although the magnitude of this treatment 
effect varied by the potency of the P2Y12 inhibitor in the 
experimental and control groups, which has important 
implications for practice.
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Fig 2 | subgroup analyses for primary endpoint of all cause death, myocardial infarction, or stroke in intention to treat population. High bleeding risk 
was defined on basis of Precise-DaPt score ≥25. *P value obtained by merging within study and across study interactions (owing to design of trials). 
†european regions pooled together and within study and across study interactions merged owing to trial designs. acs=acute coronary syndrome; 
cabg=coronary artery bypass grafting; caD=coronary artery disease; cKD=chronic kidney disease; DaPt=dual antiplatelet therapy; laD=left 
anterior descending artery; P2y12i=P2y12 inhibitor monotherapy; Pci=percutaneous coronary intervention
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rationale for P2y12 inhibitor monotherapy after 
coronary revascularisation
A six to 12 month DAPT regimen is endorsed with a 
class I recommendation after percutaneous coronary 
intervention, irrespective of the clinical presentation 
or revascularisation techniques, and after coronary 
artery bypass grafting in patients with myocardial 
infarction.12 This reflects the robust evidence 
indicating lower ischaemic risk with DAPT compared 
with aspirin monotherapy. However, DAPT invariably 
confers a heightened risk of major bleeding affecting 
mortality and morbidity,2 20 21 and its use requires 
careful assessment of the trade-off between risks and 
anticipated benefits. An individualised approach to 
the DAPT regimen, modulating the duration of P2Y12 
inhibition on a background of aspirin therapy, has 
gained consensus.1 2 4 22 However, this approach is 
poorly standardised and lacks prospective valida-
tion.1 2 An alternative approach consists of early aspirin 
withdrawal and continuation with P2Y12 inhibitor 
monotherapy up to 12 months after percutaneous 
coronary intervention or direct initiation of P2Y12 
inhibitor monotherapy after coronary artery bypass 
grafting.5-10 Trials examining this approach were 
generally powered for non-inferiority with respect 
to ischaemic endpoints,6 7 10 based on arbitrary non-
inferiority margins, and/or superiority with respect 
to bleeding or net adverse clinical events, including a 
combination of ischaemic and bleeding endpoints.6 9 10 
They mostly showed no excess of ischaemic events and 
lower bleeding rates with P2Y12 inhibitor monotherapy 
instead of DAPT. However, the imprecisions around the 
composite or individual ischaemic endpoint estimates 
entailed the loss of the entire treatment effect observed 
in historical aspirin trials.11
comparison with previous meta-analyses on 
aggregate data and implications for clinicians
Previous aggregate data meta-analyses have not 
conclusively quantified the risks and benefits of 
aspirin withdrawal in comparison with DAPT after 
coronary revascularisation, because they included 
events occurring during the initial DAPT phase, 
which was identical in both experimental and control 
regimens and might have biased treatment estimates 
towards the null.12 14 Both ischaemic events and 
bleeding events are known to cluster within the first 
month after revascularisation.23-25 In our analysis, we 
censored 30.6% of all primary composite endpoints, 
44.4% of cardiovascular deaths, 77.5% of definite 
stent thromboses, and 52.0% of BARC type 3 or type 
5 bleeding events in the included trials. These events 
had occurred during the initial DAPT phase, which was 
identical in both treatment groups. In addition, our 
individual participant data enabled us to investigate 
the consistency of treatment effects across subgroups 
of interest. Specifically, we collected in our assembled 
dataset patient and procedural characteristics affec-
ting ischaemic and/or bleeding outcomes aiming at 
determining whether P2Y12 inhibitor monotherapy 
could be associated with potential harm in high 
ischaemic risk subsets or whether the bleeding benefit 
was confined to patients at high risk of bleeding.
Our individual participant data meta-analysis 
provides confidence that aspirin withdrawal one to 
three months after percutaneous coronary intervention 
and continuation with P2Y12 inhibitor monotherapy 
also consistently preserves ischaemic protection 
compared with DAPT in patients at higher ischaemic 
risk, such as those with diabetes or acute coronary 
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Fig 3 | sex stratified analysis for primary endpoint, all cause death, cardiovascular death, myocardial infarction, or stroke in intention to treat 
population. DaPt=dual antiplatelet therapy; P2y12i=P2y12 inhibitor monotherapy
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intervention in critical coronary segments, such as 
left main or left anterior descending coronary arteries. 
The treatment effect was consistent irrespective of 
the choice of P2Y12 inhibitor monotherapy. However, 
ticagrelor was over-represented and prasugrel was 
under-represented among the newer P2Y12 inhibitors, 
and clopidogrel monotherapy was tested only in 
Asian populations in comparison with a combination 
of aspirin and clopidogrel. We ran several sensitivity 
analyses, which suggested that the observed overall 
treatment effect was robust and reproducible despite 
the inclusion or exclusion of patients who experienced 
non-fatal events during the initial DAPT phase. We also 
did confirmatory analyses in the per protocol and on-
treatment populations, which were either previously 
not conducted or conducted inconsistently across 
trials. The observation of a possible benefit of P2Y12 
inhibitor monotherapy on cardiovascular mortality, 
apparently confined to female patients, deserves 
attention. Given the number of pre-specified subgroups 
of interest and the lack of correction for multiplicity, 
this finding remains hypothesis generating. Each of 
the six included trials observed lower hazards of the 
composite ischaemic endpoint with P2Y12 inhibitor 
monotherapy compared with DAPT in female rather 
than male patients, even though none of them 
individually showed a positive treatment-by-sex 
interaction. The effect on mortality does not seem to 
be explained by a reduction in major bleeding events 
with P2Y12 inhibitor monotherapy, as both relative 
and absolute risk reductions for major bleeding were 
entirely consistent across sexes. Whether between 
sex disparity in bleeding management, as previously 
observed,26 may contribute to explaining our findings 
remains to be investigated. Given that the risks and 
benefits of aspirin may be affected by weight,27 its role 
was separately appraised in men and women. Our data 
do not support the hypothesis that weight accounts for 
the observed heterogeneity in the treatment benefit 
across sexes.
The treatment effect with P2Y12 inhibitor mono-
therapy on bleeding varied in magnitude according 
to the potency of P2Y12 inhibitor in the experimental 
and/or control groups and was apparently null when 
monotherapy with a newer P2Y12 inhibitor was 
compared with aspirin and clopidogrel. However, 
confidence intervals were large for this comparison, 
including both benefit and harm. P2Y12 inhibitor 
monotherapy therefore seems particularly appealing 
when newer P2Y12 inhibitors, rather than clopidogrel, 
are clinically favoured. In all other subgroup analyses, 
we found benefits with respect to major bleeding 
events irrespective of baseline risks and across the 
entire spectrum of included patients. Taken together, 
this suggests that the recent guideline statements that 
P2Y12 inhibitor monotherapy should be considered 
after a short course of DAPT, depending on the balance 
between the ischaemic and bleeding risk, is therefore 
no longer supported by the totality of evidence.15
Our findings are poorly informative on the choice 
of antithrombotic treatment after coronary artery 
bypass grafting.5 Firstly, only a small trial powered 
for angiographic endpoints was available for inclusion. 
Secondly, limited and controversial evidence is 
available on the value of DAPT after surgical 
revascularisation in patients with chronic coronary 
syndrome.1  2 28 Despite supportive evidence from 
subgroups of large trials after acute coronary syndrome 
for clopidogrel or ticagrelor,29 30 a DAPT regimen 
remains inconsistently implemented in practice.1 2
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Fig 4 | Primary endpoint or its components and key safety endpoint stratified by use of clopidogrel or newer P2y12 inhibitors in experimental arm of 
intention to treat population. barc=bleeding academy research consortium; DaPt=dual antiplatelet therapy
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limitations of study
The results of this individual participant data meta-
analysis should be interpreted in view of several 
limitations. The analysis is subject to the shortcomings 
of the original trials, including an open label design 
in five of the six studies.5-9 However, all studies 
implemented blinded central endpoint adjudication,31 
and endpoint definitions were largely consistent 
across trials. Cardiac instead of cardiovascular death 
was analysed in one trial because vascular death 
was not independently adjudicated.9 We excluded 
events occurring while randomised groups received 
identical DAPT regimens in four trials.6-9 However, 
sensitivity analyses including the initial DAPT phase 
following randomisation provided consistent results. 
No correction for multiple testing was pre-specified. 
Therefore, the lower risk of composite ischaemic 
endpoints with P2Y12 inhibitor monotherapy in women 
is exploratory and needs prospective validation. The 
choice of P2Y12 inhibitor monotherapy requires further 
investigation. Prasugrel monotherapy was used in a 
few patients within one trial and as protocol deviations 
in another.7 8 Four trials mandated the use of ticagrelor 
monotherapy,5 6 9 10 one study mandated clopidogrel 
monotherapy,8 and only one trial allowed and stratified 
randomisation for all three oral P2Y12 inhibitors.
7 The 
duration of P2Y12 inhibitor monotherapy ranged from 
nine to 12 months across the included trials. However, 
findings were consistent after censoring of events that 
occurred beyond nine months. Finally, six rather than 
12 month DAPT is recommended after percutaneous 
coronary intervention in patients with chronic 
coronary syndrome. However, 12 month DAPT remains 
the standard of care in many centres across the world 
in patients with chronic coronary syndrome,32 and the 
results remained largely consistent for either ischaemic 
or bleeding endpoints when stratified on the basis of 
clinical presentation.
conclusions
P2Y12 inhibitor monotherapy was associated with 
similar risks of death, myocardial infarction, or stroke 
and lower risks of major bleeding compared with 
DAPT. We found evidence that these associations 
may be modified by sex and type of P2Y12 inhibitor, 
respectively. The data on P2Y12 inhibitor monotherapy 
compared with DAPT after coronary artery bypass 
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Hazard ratio: 0.49 (95% CI 0.39 to 0.63)
Fig 5 | Hazard ratios for individual trials and for pooled population and Kaplan-Meier estimates for key safety endpoint of bleeding academic 
research consortium (barc) type 3 or type 5 bleeding in intention to treat population. Kaplan-Meier curves and hazard ratios from one step, fixed 
effect meta-analysis (top) and two step, fixed effect meta-analysis (bottom). DaPt=dual antiplatelet therapy
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investigation. Our results, based on the totality of 
the available evidence, support a paradigm shift 
in antithrombotic management and question the 
central role of DAPT beyond one to three months after 
percutaneous coronary intervention.
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